Identify the gel before comparing percentages
The label identifies Atralin as a gel containing 0.05% tretinoin by weight. Each gram therefore contains 0.5 milligrams of tretinoin. That unit conversion describes concentration, not how much a person should apply. A pharmacist can reconcile the prescribed product, container and instructions if the brand name or dosage form differs between an order and its package.
The ingredient list also includes glycerin, sodium hyaluronate and fish collagen hydrolyzates, among other vehicle components. These are details of the actual preparation. The label says the contribution of individual vehicle ingredients to efficacy has not been evaluated. It would be an overreach to turn the presence of a familiar moisturizing ingredient into proof that this gel is gentler than every cream.
Two products sharing a percentage can have different supporting formulations and directions. Our prescription-label guide explains the fields worth matching. The word gel is not a complete prediction of how a particular person's skin will respond.
What its acne studies measured
Atralin was assessed in two randomized, controlled studies lasting twelve weeks in people with mild to moderate acne. The comparison was its vehicle, meaning the preparation without the active tretinoin. The trials measured acne lesion counts and an investigator-rated severity outcome; they were not trials of fine-wrinkle treatment or a comparison with a telehealth compound.
In the first trial, the label reports global-severity success in 21% of the Atralin group and 12% of the vehicle group. In the second, it reports 23% and 14%, respectively. Success meant clear or very mild acne; the second trial also required at least a two-grade reduction from baseline. Those definitions belong beside the percentages because success did not necessarily mean every lesion disappeared.
Mean total facial lesion reductions were 43% versus 22% in the first trial, and 35% versus 19% in the second. A mean is an average across participants. It is neither a personal forecast nor a guarantee that an individual will achieve that reduction at a particular visit. The different success definitions also discourage casually pooling both trials into one headline rate.
Age and representation limit the conclusions
Participants ranged from ten to sixty-five years old. The label describes a population that was approximately 52% female and 74% Caucasian, with other racial groups represented in smaller proportions. It explicitly says the database was not large enough to determine differences in effects between age, sex or race subgroups.
An upper age in a trial is not proof that many participants were near that age. Nor does a subgroup limitation show that a medicine cannot help anyone outside the dominant group. It tells us what the available comparison cannot confidently resolve. The guide to tretinoin evidence after sixty-five explores that distinction without converting it into an age-based treatment rule.
The acne indication also matters when the goal is facial texture or lines. Evidence for one condition cannot simply be renamed evidence for another. Our acne-versus-photoaging guide separates those outcomes and the relevant product labels.
Irritation deserves a usable follow-up plan
In the label's combined trials, dry skin occurred in 16% of Atralin recipients versus 2% of vehicle recipients; peeling, scaling or flaking occurred in 12% versus 1%. Burning and redness were also reported. These figures describe selected events in those trials, not the probability for every age, skin condition or combination of products.
The label cautions about eczema, sunburn, irritating cleansers and other topical treatments. It also addresses sunlight and environmental exposure. These warnings make a current product list useful at a prescribing visit: a cleanser, acne treatment or exfoliant can matter even when it is bought without a prescription.
There is no need to interpret painful irritation as evidence of success. Ask how to contact the prescribing team, which symptoms need prompt assessment and how they will decide whether a reaction is expected irritation or something else. Our first-month questions organize that conversation without supplying a dose or a self-directed adjustment schedule.
The fish-allergy detail is product specific
Atralin's label contains a fish-allergy precaution because of the fish-derived material in its formulation. A person with a fish allergy should make that history visible to the prescriber and pharmacist before using it. The patient information also tells users to report itching or hives to their healthcare provider.
That warning does not mean every tretinoin preparation contains fish proteins, or that a different product is automatically suitable. It illustrates why reviewing the full ingredient list can change a decision that looked straightforward when only the active percentage was considered. A previous reaction should be described by the product, symptoms and timing, rather than reduced to the assumption that all retinoids are interchangeable.
Pregnancy planning, pregnancy and breastfeeding also require a separate clinical discussion. MedlinePlus and the product information address these histories; they are not questions a review score can settle. Our pregnancy and breastfeeding guide explains the evidence boundaries.
Price and access remain separate checks
The public label does not establish the current cash price, an insurance copay, a dispensing pharmacy's stock or whether an online service can prescribe the product in a particular state. A useful quote identifies the exact brand or authorized substitute, strength, container size, dispensing fee and any separate consultation charge.
Compare that quote with the actual order period. A tube's labeled quantity does not by itself reveal a personal monthly cost because prescribed use and the usable date matter. The subscription-cost guide explains why delivery intervals, upfront totals and billing arrangements need their own line in the comparison.
Atralin's clearest documented advantage for evaluation is the availability of product-specific labeling and controlled acne data. That is an evidence characteristic, not a declaration that it is the best choice for a reader. A practical decision still requires a confirmed diagnosis, suitability assessment, exact product quote and a reachable clinician when questions arise.